Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Tourmaline Bio, Inc. Director's Dealing 2021

May 7, 2021

32658_dirs_2021-05-06_22546fee-006f-4cb9-8cea-97cd662b8f8e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Talaris Therapeutics, Inc. (TALS)
CIK: 0001827506
Period of Report: 2021-05-06

Reporting Person: GALAKATOS NICHOLAS (Director)

More from Tourmaline Bio, Inc.

Regulatory Filings 2025
Nov 17
Regulatory Filings 2025
Nov 17
Major Shareholding Notification 2025
Nov 14
Regulatory Filings 2025
Nov 7
Director's Dealing 2025
Oct 28
Director's Dealing 2025
Oct 28
Director's Dealing 2025
Oct 28
Director's Dealing 2025
Oct 28
Director's Dealing 2025
Oct 28
Director's Dealing 2025
Oct 28
View all filings →